chartexchange

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

PR Newswire | Nov 4, 2026 9:01 AM EST

– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage...

Read original article